Autopsy report · NCT00315458

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

“Administrative reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 4 months after it had already started.
• Ran for about 1 year 3 months before it stopped.
• 107 participants enrolled.
• Results were posted on the registry 5 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Purdue Pharma LP

Sponsor type

Industry

Conditions

Osteoarthritis

Interventions

Buprenorphine transdermal patch; Placebo transdermal patch

Participants

107

Sites

48

Countries

United States

Trials that died the same way

• An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
  “Administrative Reason” (88% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
  “Due to administrative reasons” (80% match in meaning)
• RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
  “Business reasons.” (79% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (78% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.